ALKS vs CSTL: fair value comparison
Alkermes plc and Castle Biosciences, Inc. · Updated 2026-10-19
CSTL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ALKS currently ranks higher by quality score.
| ALKS | CSTL | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $41.22 | $31.96 |
| 12-month range | $27.20–$55.22 | $18.15–$43.04 |
| Rank by discount to fair value | #91 of 108 Healthcare | — |
| Rank by quality score | #48 of 301 Healthcare | #50 of 301 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ALKS fair value analysis · CSTL fair value analysis